Biotechnological Company Moleculin Biotech selects Bioscience SA as Polish CRO.
Biotechnological Company Moleculin Biotech, Inc. Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO.
Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at the MD Anderson Cancer Center.
“Engaging Bioscience gives us experienced boots on the ground in Poland,” commented Walter Klemp, CEO of Moleculin, “which we believe is critical, not only for ensuring tight coordination between the US and Polish sites in our upcoming Annamycin clinical trial (which would commence only if our IND for Annamycin is permitted), but also to ensure we have the full benefit of local knowledge regarding site performance and regulatory compliance.”
Mr. Klemp continued: “one of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently.”
More about Moleculin: http://ir.moleculin.com/